ITRM20100121A1 - Marcatori molecolari per infezioni delle vie urinarie. - Google Patents
Marcatori molecolari per infezioni delle vie urinarie. Download PDFInfo
- Publication number
- ITRM20100121A1 ITRM20100121A1 IT000121A ITRM20100121A ITRM20100121A1 IT RM20100121 A1 ITRM20100121 A1 IT RM20100121A1 IT 000121 A IT000121 A IT 000121A IT RM20100121 A ITRM20100121 A IT RM20100121A IT RM20100121 A1 ITRM20100121 A1 IT RM20100121A1
- Authority
- IT
- Italy
- Prior art keywords
- procalcitonin
- urinary tract
- concentration
- urine
- aliquots
- Prior art date
Links
- 230000002485 urinary effect Effects 0.000 title description 20
- 208000015181 infectious disease Diseases 0.000 title description 11
- 108010048233 Procalcitonin Proteins 0.000 claims description 103
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 claims description 103
- 210000002700 urine Anatomy 0.000 claims description 57
- 208000019206 urinary tract infection Diseases 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 31
- 238000003745 diagnosis Methods 0.000 claims description 14
- MJKVTPMWOKAVMS-UHFFFAOYSA-N 3-hydroxy-1-benzopyran-2-one Chemical compound C1=CC=C2OC(=O)C(O)=CC2=C1 MJKVTPMWOKAVMS-UHFFFAOYSA-N 0.000 claims description 12
- 238000000338 in vitro Methods 0.000 claims description 9
- 238000012544 monitoring process Methods 0.000 claims description 9
- 229910052693 Europium Inorganic materials 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 claims description 7
- QWZHDKGQKYEBKK-UHFFFAOYSA-N 3-aminochromen-2-one Chemical compound C1=CC=C2OC(=O)C(N)=CC2=C1 QWZHDKGQKYEBKK-UHFFFAOYSA-N 0.000 claims description 6
- 229910052772 Samarium Inorganic materials 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 6
- HQCYVSPJIOJEGA-UHFFFAOYSA-N methoxycoumarin Chemical compound C1=CC=C2OC(=O)C(OC)=CC2=C1 HQCYVSPJIOJEGA-UHFFFAOYSA-N 0.000 claims description 6
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 claims description 6
- 239000013642 negative control Substances 0.000 claims description 5
- 239000013641 positive control Substances 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 3
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 14
- 101100311210 Mus musculus Stard10 gene Proteins 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 229940109239 creatinine Drugs 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 4
- 239000000700 radioactive tracer Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001635 urinary tract Anatomy 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000011698 potassium fluoride Substances 0.000 description 2
- 235000003270 potassium fluoride Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000008085 renal dysfunction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 201000003126 Anuria Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- ZKKLPDLKUGTPME-UHFFFAOYSA-N diazanium;bis(sulfanylidene)molybdenum;sulfanide Chemical compound [NH4+].[NH4+].[SH-].[SH-].S=[Mo]=S ZKKLPDLKUGTPME-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000009112 empiric therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- GWQVMPWSEVRGPY-UHFFFAOYSA-N europium cryptate Chemical compound [Eu+3].N=1C2=CC=CC=1CN(CC=1N=C(C=CC=1)C=1N=C(C3)C=CC=1)CC(N=1)=CC(C(=O)NCCN)=CC=1C(N=1)=CC(C(=O)NCCN)=CC=1CN3CC1=CC=CC2=N1 GWQVMPWSEVRGPY-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000012332 laboratory investigation Methods 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- JPMIIZHYYWMHDT-UHFFFAOYSA-N octhilinone Chemical compound CCCCCCCCN1SC=CC1=O JPMIIZHYYWMHDT-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/585—Calcitonins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/348—Urinary tract infections
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Absorbent Articles And Supports Therefor (AREA)
- External Artificial Organs (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000121A ITRM20100121A1 (it) | 2010-03-18 | 2010-03-18 | Marcatori molecolari per infezioni delle vie urinarie. |
| EP11713086.4A EP2548031B1 (en) | 2010-03-18 | 2011-03-15 | Molecular markers for urinary tract infections |
| JP2012557648A JP5681219B2 (ja) | 2010-03-18 | 2011-03-15 | 尿管感染症のための分子マーカー |
| ES11713086.4T ES2484720T3 (es) | 2010-03-18 | 2011-03-15 | Marcadores moleculares para infecciones de las vías urinarias |
| US13/635,521 US8748195B2 (en) | 2010-03-18 | 2011-03-15 | Molecular markers for urinary tract infections |
| CN201180014501.XA CN102939542B (zh) | 2010-03-18 | 2011-03-15 | 用于泌尿道感染的分子标记物 |
| HK13107403.1A HK1180392B (en) | 2010-03-18 | 2011-03-15 | Molecular markers for urinary tract infections |
| RU2012144233A RU2611371C2 (ru) | 2010-03-18 | 2011-03-15 | Молекулярные маркеры для инфекций мочевыводящих путей |
| BR112012023485-4A BR112012023485B1 (pt) | 2010-03-18 | 2011-03-15 | Marcadores moleculares para infecções do trato urinário |
| PCT/IB2011/051073 WO2011114287A2 (en) | 2010-03-18 | 2011-03-15 | Molecular markers for urinary tract infections |
| ZA2012/06633A ZA201206633B (en) | 2010-03-18 | 2012-09-04 | Molecular markers for urinary tract infections |
| US14/267,366 US20140242725A1 (en) | 2010-03-18 | 2014-05-01 | Molecular markers for urinary tract infections |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000121A ITRM20100121A1 (it) | 2010-03-18 | 2010-03-18 | Marcatori molecolari per infezioni delle vie urinarie. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ITRM20100121A1 true ITRM20100121A1 (it) | 2011-09-19 |
Family
ID=42630320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT000121A ITRM20100121A1 (it) | 2010-03-18 | 2010-03-18 | Marcatori molecolari per infezioni delle vie urinarie. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8748195B2 (https=) |
| EP (1) | EP2548031B1 (https=) |
| JP (1) | JP5681219B2 (https=) |
| CN (1) | CN102939542B (https=) |
| BR (1) | BR112012023485B1 (https=) |
| ES (1) | ES2484720T3 (https=) |
| IT (1) | ITRM20100121A1 (https=) |
| RU (1) | RU2611371C2 (https=) |
| WO (1) | WO2011114287A2 (https=) |
| ZA (1) | ZA201206633B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2592228C2 (ru) * | 2014-04-10 | 2016-07-20 | Владимир Игоревич Павлов | Способ (варианты) и набор для диагностики инфекции мочевыводящих путей, способ лечения и определения предрасположенности к инфекции мочевыводящих путей |
| RU2679629C1 (ru) * | 2018-07-05 | 2019-02-12 | Антонина Ни | Способ диагностики воспалительного процесса органов мочевыделительной системы у детей раннего возраста |
| RU2724186C1 (ru) * | 2020-01-23 | 2020-06-22 | Наталья Борисовна Гусева | Способ лечения детей раннего возраста с рецидивирующей инфекцией мочевой системы |
| RU2766811C1 (ru) * | 2021-06-22 | 2022-03-15 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Тихоокеанский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ применения маркеров бактериального воспаления для диагностики инфекции мочевыводящих путей у детей первых трех лет жизни |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100056763A1 (en) * | 2007-02-28 | 2010-03-04 | B.R.A.H.M.S Aktiengesellschaft | Method for the selective determination of procalcitonin 1-116 for diagnostic purposes and antibodies and kits for carrying out such a method |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| BRPI0616720A2 (pt) * | 2005-09-28 | 2011-06-28 | Becton Dickinson Co | método para o diagnóstico ou prognóstico de sepse em um paciente, kit para diagnóstico ou prognóstico, ou monitoração, de sepse em um paciente, e, dispositivo para o diagnóstico ou prognóstico de sepse |
| CN103123359B (zh) * | 2007-08-03 | 2015-07-29 | B.R.A.H.M.S有限公司 | 降钙素原(pct)在患原发性非传染疾病的患者的风险分级和预后中的应用 |
| JP5722587B2 (ja) * | 2009-10-13 | 2015-05-20 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 急性脳卒中または一過性脳虚血発作を有する患者における細菌感染の診断のためのプロカルシトニン及び抗生物質治療のガイダンス |
| JP5798133B2 (ja) * | 2010-03-08 | 2015-10-21 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 不特定の愁訴を示す患者における細菌感染及び抗生物質治療の指標を診断するために用いられるプロカルシトニン |
| KR102045300B1 (ko) * | 2010-05-04 | 2019-11-18 | 에티컨, 엘엘씨 | 레이저 커팅된 리테이너를 갖는 자가-유지형 시스템 |
-
2010
- 2010-03-18 IT IT000121A patent/ITRM20100121A1/it unknown
-
2011
- 2011-03-15 EP EP11713086.4A patent/EP2548031B1/en active Active
- 2011-03-15 ES ES11713086.4T patent/ES2484720T3/es active Active
- 2011-03-15 US US13/635,521 patent/US8748195B2/en active Active
- 2011-03-15 WO PCT/IB2011/051073 patent/WO2011114287A2/en not_active Ceased
- 2011-03-15 CN CN201180014501.XA patent/CN102939542B/zh active Active
- 2011-03-15 BR BR112012023485-4A patent/BR112012023485B1/pt active IP Right Grant
- 2011-03-15 RU RU2012144233A patent/RU2611371C2/ru active
- 2011-03-15 JP JP2012557648A patent/JP5681219B2/ja active Active
-
2012
- 2012-09-04 ZA ZA2012/06633A patent/ZA201206633B/en unknown
-
2014
- 2014-05-01 US US14/267,366 patent/US20140242725A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100056763A1 (en) * | 2007-02-28 | 2010-03-04 | B.R.A.H.M.S Aktiengesellschaft | Method for the selective determination of procalcitonin 1-116 for diagnostic purposes and antibodies and kits for carrying out such a method |
Non-Patent Citations (9)
| Title |
|---|
| AYAZI P ET AL: "Comparison of procalcitonin and C-reactive protein tests in children with urinary tract infection", IRANIAN JOURNAL OF PEDIATRICS, vol. 19, no. 4, 2009, pages 381 - 386, XP002598544 * |
| GENDREL D: "[Urinary tract infection and biological markers: C-reactive protein, interleukins and procalcitonin]", ARCHIVES DE PÉDIATRIE, vol. 5 Suppl 3, 1998, pages 269S - 273S, XP002598545 * |
| GENDREL DOMINIQUE ET AL: "Procalcitonin and prediction of vesico-ureteral reflux in pediatric urinary tract infection", BULLETIN, ACADEMIE NATIONALE DE MEDECINE, vol. 191, no. 8, 2007, pages 1731 - 1744, XP009124548 * |
| KOTOULA A ET AL: "Comparative Efficacies of Procalcitonin and Conventional Inflammatory Markers for Prediction of Renal Parenchymal Inflammation in Pediatric First Urinary Tract Infection", UROLOGY, vol. 73, no. 4, 2009, pages 782 - 786, XP026060730 * |
| LAI C -C ET AL K ET AL: "Diagnostic value of procalcitonin for bacterial infection in elderly patients in the emergency department", JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, vol. 58, no. 3, 16 February 2010 (2010-02-16), pages 518 - 522, XP002598542 * |
| LEROY ET AL: "Procalcitonin to reduce the number of unnecessary cystographies in children with a urinary tract infection: A european validation study", JOURNAL OF PEDIATRICS, vol. 150, no. 1, 2007, pages 89 - 95, XP005930752 * |
| LEROY SANDRINE ET AL: "Procalcitonin as a predictor of vesicoureteral reflux in children with a first febrile urinary tract infection.", PEDIATRICS, vol. 115, no. 6, 2005, pages E706 - E709, XP002598546 * |
| NANDA NEHA ET AL: "Novel biomarkers for the diagnosis of urinary tract infection-a systematic review.", BIOMARKER INSIGHTS, vol. 4, 2009, pages 111 - 121, XP002598543 * |
| VAN ROSSUM A ET AL: "Procalcitonin as an early marker of infection in neonates and children", LANCET INFECTIOUS DISEASES, vol. 4, no. 10, 2004, pages 620 - 630, XP023906010 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2548031A2 (en) | 2013-01-23 |
| ES2484720T3 (es) | 2014-08-12 |
| HK1180392A1 (en) | 2013-10-18 |
| US8748195B2 (en) | 2014-06-10 |
| BR112012023485B1 (pt) | 2020-03-17 |
| EP2548031B1 (en) | 2014-05-21 |
| BR112012023485A2 (pt) | 2016-05-24 |
| JP2013522618A (ja) | 2013-06-13 |
| RU2012144233A (ru) | 2014-04-27 |
| CN102939542A (zh) | 2013-02-20 |
| WO2011114287A2 (en) | 2011-09-22 |
| RU2611371C2 (ru) | 2017-02-21 |
| CN102939542B (zh) | 2015-07-08 |
| JP5681219B2 (ja) | 2015-03-04 |
| US20140242725A1 (en) | 2014-08-28 |
| WO2011114287A3 (en) | 2011-12-15 |
| ZA201206633B (en) | 2015-04-29 |
| US20130084650A1 (en) | 2013-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Luyt et al. | Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia | |
| Horonenko et al. | Soluble triggering receptor expressed on myeloid cell-1 is increased in patients with ventilator-associated pneumonia: a preliminary report | |
| ES2944613T3 (es) | proADM y/o histonas como marcadores indicadores de un acontecimiento adverso | |
| AU2007234504A1 (en) | Method for differentiating irritable bowel syndrome from inflammatory bowel disease (IBD) and for monitoring persons with IBD using total endogenous lactofferin as a marker | |
| US20130288276A1 (en) | Method for prediction of prognosis of sepsis | |
| CA2502976A1 (en) | Inflammatory bowel disease and irritable bowel syndrome ibd-first chek diagnostic panel | |
| WO2014068018A1 (en) | Methods of prognosis and diagnosis of sepsis | |
| ITRM20100121A1 (it) | Marcatori molecolari per infezioni delle vie urinarie. | |
| US20130149725A1 (en) | Methods and compositions for diagnosis of urosepsis and urinary tract infection | |
| CA2554899C (en) | Method and kit for the measurement of neutrophil cell activation | |
| WO2020085803A1 (ko) | 인지기능 정상군 또는 경도 인지장애에서 아밀로이드 베타의 뇌 침착 검출용 혈액 바이오 마커 | |
| Hausfater et al. | Procalcitonin measurement in routine emergency medicine practice: comparison between two immunoassays | |
| JP2024020276A (ja) | 歯肉炎の診断方法、使用、キット | |
| US9435815B2 (en) | Method for rapid detection of hepatocyte growth factor in biological fluids | |
| CN112114138A (zh) | 一种儿童肺炎支原体抗原的检测试剂盒及检测方法 | |
| CN102292639A (zh) | 检测抗睾丸抗原自身抗体的免疫测试 | |
| HK1180392B (en) | Molecular markers for urinary tract infections | |
| Bhardwaj et al. | Prognostic role of NGAL in critically ill patients | |
| JPH1132793A (ja) | 尿路感染症の診断キット | |
| WO2026008623A1 (en) | A method for the diagnosis of a urinary tract infection | |
| WO2026029044A1 (ja) | うつ病または統合失調症の診断などを補助する方法、キットおよびバイオマーカー | |
| JP6207501B2 (ja) | 肺炎球菌性肺炎の重症度判定方法 | |
| Mahadev et al. | A study of serum procalcitonin (PCT) as a diagnostic biomarker in sepsis in ICU | |
| CN108387733A (zh) | 一种基于双分子荧光互补技术的mALB检测试剂盒、制备及使用方法 | |
| HK1132038A (en) | Method for monitoring persons with ibd using total endogeneous lactoferrin as a marker |